{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"pt-141-gut","title":"PT-141 for Gut: Evidence Review","body":"## What's breaking down\n\nGut issues often involve layers of degeneration where repair pathways lag behind ongoing stress or inflammation. The melanocortin system, which PT-141 targets in the central nervous system, has some presence in broader physiology, but direct links to intestinal tissue repair remain unexplored in available data. If your gut symptoms tie into central arousal or motivation pathways, or if side effects like nausea appear, that context matters. PT-141 is not positioned as a gut-specific compound.\n\n## Why PT-141 might help you\n\n1. **Therefore for you:** If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\n\nPT-141 acts centrally on melanocortin receptors, primarily MC4R in the hypothalamus. This pathway influences arousal and motivation. For someone whose gut complaints overlap with disrupted CNS signaling (such as stress-related motility changes), the discussion centers on whether central activation could indirectly support gut-brain communication. No direct tissue repair data exists for intestinal lining or microbiome balance. If your gut problem stems from mechanical or inflammatory breakdown rather than CNS arousal, this mechanism does not address those layers. Side effect reports note slowed gastric emptying and nausea, which could add mechanical load or discomfort rather than relieve it.\n\n## How these fit together\n\nSingle-compound focus. PT-141 maps to the sexual / CNS arousal layer. If your condition profile includes a multi-peptide stack, siblings would target other layers listed in the condition profile. Here the focus stays on one compound and one primary layer.\n\n## What the evidence actually shows\n\nHuman trials of bremelanotide focus on hypoactive sexual desire disorder. Two phase 3 studies measured desire scores and distress but did not assess gastrointestinal endpoints beyond recording adverse events. Nausea occurred in roughly 40 percent of participants at the approved dose, with some reports of stomach pain and slowed gastric emptying. These effects led to cautions for people with existing bowel motility problems. Preclinical work includes one rabbit ileum study where alpha-MSH (related but not identical) produced relaxation; bremelanotide itself showed no comparable effect at the tested concentration. No rodent or human studies demonstrate PT-141 repairing gut mucosa, reducing inflammation markers, or improving motility in disease models. Anecdotal reports on forums mention nausea or stomach upset after use, with no consistent claims of gut improvement.\n\n## What scientists say\n\nPublished reviews describe bremelanotide as a melanocortin agonist acting in the medial preoptic area to increase dopamine release linked to sexual motivation. Gastrointestinal effects appear only in safety sections as dose-dependent adverse events. Researchers note the drug's metabolism involves peptide hydrolysis, with no identified gut-protective pathway. Functional MRI studies in women with HSDD show changes in sexual brain processing but do not extend to gut regions or autonomic control of digestion.\n\n## What people say on Reddit\n\nUsers in threads about PT-141 experiences frequently list nausea, stomach discomfort, or vomiting as first-dose effects that may lessen with repeated lower dosing or antihistamine pretreatment. Some report taking the compound on an empty stomach to reduce queasiness. No posts describe resolution of IBS, ulcer healing, or improved digestion; discussions stay centered on sexual response and side-effect management. Several users note the peptide is destroyed if taken orally due to digestion.\n\n## What people say on X\n\nPosts referencing PT-141 rarely mention gut outcomes. Occasional comments link the compound to broader peptide stacks or note transient nausea. One post in a Huberman Lab discussion thread lists PT-141 alongside other peptides without gut-specific claims. Sentiment remains focused on libido effects rather than digestive repair.\n\n## What we do not know\n\nNo controlled human data exist on PT-141 for any primary gut condition. Long-term effects on gastric emptying or microbiome composition are unstudied. Whether central melanocortin activation could produce secondary benefits in stress-sensitive gut disorders remains speculative. Animal models of intestinal disease have not tested this compound.\n\n## Safety and limits\n\nCommon side effects include nausea, flushing, and headache. The drug carries a caution for use in people with slow gastric emptying because it may worsen the condition and alter absorption of oral medications. It is administered by subcutaneous injection. Evidence grade for any gut benefit is absent; available information addresses sexual function and lists gastrointestinal adverse events. Readers should consult primary sources and qualified professionals for personal decisions.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/pt-141-gut/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"Bremelanotide is approved for HSDD and commonly causes nausea in ~40% of users in phase 3 trials.","section":"What the evidence actually shows","tier":"human","source_ids":["s0","s4"],"source_status":"sourced","why_material":"Establishes the main documented human effect relevant to gut symptoms.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:16:04.509Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"No published human or animal studies show PT-141 repairing intestinal tissue or improving gut motility disorders.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s22"],"source_status":"sourced","why_material":"Clarifies absence of positive gut data.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:16:04.509Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Reddit users report nausea or stomach upset as the dominant gut-related experience with PT-141.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s15"],"source_status":"sourced","why_material":"Documents real-world reports separate from trials.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:16:04.509Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s0","type":"medical","url":"https://www.mayoclinic.org/drugs-supplements/bremelanotide-subcutaneous-route/description/drg-20466805","title":"Bremelanotide (subcutaneous route) - Side effects & dosage","quote":"Stomach or bowel problem (eg, slow gastric emptying)—Use with caution. May make this condition worse and decrease the absorption of oral medicines.","summary":"Mayo Clinic entry lists GI cautions and common side effects including nausea and stomach pain.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:16:04.133Z","link_status":"http_403","quote_status":"unverified","prev":"genesis","hash":"5249c405c2cd8485aef049d45066aaeff0a97fc5b0562c41e01079695ec4390d"},{"id":"s4","type":"other","url":"https://mensreproductivehealth.com/pt-141-for-men-a-new-drug-to-treat-erectile-dysfunction-and-low-libido/","title":"PT-141 FOR MEN","quote":"about 40% of people (based on female trials) experienced nausea after a 1.75 mg dose","summary":"Summarizes trial nausea rates and gastric emptying effects.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:16:04.133Z","link_status":"ok","quote_status":"verified","prev":"5249c405c2cd8485aef049d45066aaeff0a97fc5b0562c41e01079695ec4390d","hash":"46616f84ff4bf6fbb652e40836c0def4ab8458e19e25026fef9b5b79855af28c"},{"id":"s22","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/18587425/","title":"Pharmacological profiling of neuropeptides on rabbit ileum","quote":"The melanocortin agonist alpha-melanocortin-stimulating hormone (1 microM), but not bremelanotide (1 microM), also relaxed both preparations.","summary":"Only related compound showed effect; bremelanotide did not.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:16:04.133Z","link_status":"ok","quote_status":"verified","prev":"46616f84ff4bf6fbb652e40836c0def4ab8458e19e25026fef9b5b79855af28c","hash":"8e998c5e33732bb8c8cafa52a470a68e674cb0bce776a2678accdc9bd0b0bb09"},{"id":"s15","type":"reddit","url":"https://www.reddit.com/r/erectiledysfunction/comments/1qik4vm/pt141_experience_it_absolutely_works/","title":"PT-141 Experience","quote":"No pill form as it is a peptide it would be digested in the stomach.","summary":"User discussion of administration and side effects.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:16:04.133Z","link_status":"ok","quote_status":"unverified","prev":"8e998c5e33732bb8c8cafa52a470a68e674cb0bce776a2678accdc9bd0b0bb09","hash":"0bc46685450ce81ea92026cc60141ec391df3757b8f815c3524e1755dbe6ed9e"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-30T01:16:04.899Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"PT-141 for Gut: Evidence Review","register":"source_ledger","body":"## What's breaking down\n\nGut issues often involve layers of degeneration where repair pathways lag behind ongoing stress or inflammation. The melanocortin system, which PT-141 targets in the central nervous system, has some presence in broader physiology, but direct links to intestinal tissue repair remain unexplored in available data. If your gut symptoms tie into central arousal or motivation pathways, or if side effects like nausea appear, that context matters. PT-141 is not positioned as a gut-specific compound.\n\n## Why PT-141 might help you\n\n1. **Therefore for you:** If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\n\nPT-141 acts centrally on melanocortin receptors, primarily MC4R in the hypothalamus. This pathway influences arousal and motivation. For someone whose gut complaints overlap with disrupted CNS signaling (such as stress-related motility changes), the discussion centers on whether central activation could indirectly support gut-brain communication. No direct tissue repair data exists for intestinal lining or microbiome balance. If your gut problem stems from mechanical or inflammatory breakdown rather than CNS arousal, this mechanism does not address those layers. Side effect reports note slowed gastric emptying and nausea, which could add mechanical load or discomfort rather than relieve it.\n\n## How these fit together\n\nSingle-compound focus. PT-141 maps to the sexual / CNS arousal layer. If your condition profile includes a multi-peptide stack, siblings would target other layers listed in the condition profile. Here the focus stays on one compound and one primary layer.\n\n## What the evidence actually shows\n\nHuman trials of bremelanotide focus on hypoactive sexual desire disorder. Two phase 3 studies measured desire scores and distress but did not assess gastrointestinal endpoints beyond recording adverse events. Nausea occurred in roughly 40 percent of participants at the approved dose, with some reports of stomach pain and slowed gastric emptying. These effects led to cautions for people with existing bowel motility problems. Preclinical work includes one rabbit ileum study where alpha-MSH (related but not identical) produced relaxation; bremelanotide itself showed no comparable effect at the tested concentration. No rodent or human studies demonstrate PT-141 repairing gut mucosa, reducing inflammation markers, or improving motility in disease models. Anecdotal reports on forums mention nausea or stomach upset after use, with no consistent claims of gut improvement.\n\n## What scientists say\n\nPublished reviews describe bremelanotide as a melanocortin agonist acting in the medial preoptic area to increase dopamine release linked to sexual motivation. Gastrointestinal effects appear only in safety sections as dose-dependent adverse events. Researchers note the drug's metabolism involves peptide hydrolysis, with no identified gut-protective pathway. Functional MRI studies in women with HSDD show changes in sexual brain processing but do not extend to gut regions or autonomic control of digestion.\n\n## What people say on Reddit\n\nUsers in threads about PT-141 experiences frequently list nausea, stomach discomfort, or vomiting as first-dose effects that may lessen with repeated lower dosing or antihistamine pretreatment. Some report taking the compound on an empty stomach to reduce queasiness. No posts describe resolution of IBS, ulcer healing, or improved digestion; discussions stay centered on sexual response and side-effect management. Several users note the peptide is destroyed if taken orally due to digestion.\n\n## What people say on X\n\nPosts referencing PT-141 rarely mention gut outcomes. Occasional comments link the compound to broader peptide stacks or note transient nausea. One post in a Huberman Lab discussion thread lists PT-141 alongside other peptides without gut-specific claims. Sentiment remains focused on libido effects rather than digestive repair.\n\n## What we do not know\n\nNo controlled human data exist on PT-141 for any primary gut condition. Long-term effects on gastric emptying or microbiome composition are unstudied. Whether central melanocortin activation could produce secondary benefits in stress-sensitive gut disorders remains speculative. Animal models of intestinal disease have not tested this compound.\n\n## Safety and limits\n\nCommon side effects include nausea, flushing, and headache. The drug carries a caution for use in people with slow gastric emptying because it may worsen the condition and alter absorption of oral medications. It is administered by subcutaneous injection. Evidence grade for any gut benefit is absent; available information addresses sexual function and lists gastrointestinal adverse events. Readers should consult primary sources and qualified professionals for personal decisions.","claims":[{"id":"c1","text":"Bremelanotide is approved for HSDD and commonly causes nausea in ~40% of users in phase 3 trials.","section":"What the evidence actually shows","tier":"human","source_ids":["s0","s4"],"source_status":"sourced","why_material":"Establishes the main documented human effect relevant to gut symptoms.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:16:04.509Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"No published human or animal studies show PT-141 repairing intestinal tissue or improving gut motility disorders.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s22"],"source_status":"sourced","why_material":"Clarifies absence of positive gut data.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:16:04.509Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Reddit users report nausea or stomach upset as the dominant gut-related experience with PT-141.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s15"],"source_status":"sourced","why_material":"Documents real-world reports separate from trials.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:16:04.509Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s0","type":"medical","url":"https://www.mayoclinic.org/drugs-supplements/bremelanotide-subcutaneous-route/description/drg-20466805","title":"Bremelanotide (subcutaneous route) - Side effects & dosage","quote":"Stomach or bowel problem (eg, slow gastric emptying)—Use with caution. May make this condition worse and decrease the absorption of oral medicines.","link_status":"http_403","quote_status":"unverified"},{"id":"s4","type":"other","url":"https://mensreproductivehealth.com/pt-141-for-men-a-new-drug-to-treat-erectile-dysfunction-and-low-libido/","title":"PT-141 FOR MEN","quote":"about 40% of people (based on female trials) experienced nausea after a 1.75 mg dose","link_status":"ok","quote_status":"verified"},{"id":"s22","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/18587425/","title":"Pharmacological profiling of neuropeptides on rabbit ileum","quote":"The melanocortin agonist alpha-melanocortin-stimulating hormone (1 microM), but not bremelanotide (1 microM), also relaxed both preparations.","link_status":"ok","quote_status":"verified"},{"id":"s15","type":"reddit","url":"https://www.reddit.com/r/erectiledysfunction/comments/1qik4vm/pt141_experience_it_absolutely_works/","title":"PT-141 Experience","quote":"No pill form as it is a peptide it would be digested in the stomach.","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":14847,"tokens_out":2764,"cost":0.02546875,"prev_hash":"genesis","hash":"05815fb669fb21707ab4f425b35bed80adcb8b7225f66cc560242f14a9601307"}],"provenance":[{"ts":"2026-06-30T01:16:04.899Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: PT 141 for Gut\nSlug: pt-141-gut\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"pt-141\",\"name\":\"PT-141\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"pt-141\",\"name\":\"PT-141\",\"section_title\":\"Why PT-141 might help you\",\"layer\":\"sexual / CNS arousal\",\"steps\":[\"**Therefore for you:** If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. **Therefore for you:** If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **PT-141** → sexual / CNS arousal\",\"section_headings\":[\"What's breaking down\",\"Why PT-141 might help you\",\"How these fit together\",\"What the evidence actually shows\",\"What scientists say\",\"What people say on Reddit\",\"What people say on X\",\"What we do not know\",\"Safety and limits\"],\"writer_rules\":[\"One ## section per compound in peptide_chains — do not merge into one peptide essay.\",\"Each Why section must use if-then steps from peptide_chains / ","response":"{\n  \"slug\": \"pt-141-gut\",\n  \"title\": \"PT-141 for Gut: Evidence Review\",\n  \"body\": \"## What's breaking down\\n\\nGut issues often involve layers of degeneration where repair pathways lag behind ongoing stress or inflammation. The melanocortin system, which PT-141 targets in the central nervous system, has some presence in broader physiology, but direct links to intestinal tissue repair remain unexplored in available data. If your gut symptoms tie into central arousal or motivation pathways, or if side effects like nausea appear, that context matters. PT-141 is not positioned as a gut-specific compound.\\n\\n## Why PT-141 might help you\\n\\n1. **Therefore for you:** If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\\n\\nPT-141 acts centrally on melanocortin receptors, primarily MC4R in the hypothalamus. This pathway influences arousal and motivation. For someone whose gut complaints overlap with disrupted CNS signaling (such as stress-related motility changes), the discussion centers on whether central activation could indirectly support gut-brain communication. No direct tissue repair data exists for intestinal lining or microbiome balance. If your gut problem stems from mechanical or inflammatory breakdown rather than CNS arousal, this mechanism does not address those layers. Side effect reports note slowed gastric emptying and nausea, which could add mechanical load or discomfort rather than relieve it.\\n\\n## How these fit together\\n\\nSingle-compound focus. PT-141 maps to the sexual / CNS arousal layer. If your condition profile includes a multi-peptide stack, siblings would target other layers listed in the condition profile. Here the focus stays on one compound and one primary layer.\\n\\n## What the evidence actually shows\\n\\nHuman trials of bremelanotide focus on hypoactive sexual desire disorder. Two phase 3 studies measured desire scores and distress but did not assess gastrointestinal endpoints ","tokens_in":14847,"tokens_out":2764,"cost":0,"prev":"genesis","hash":"ddfeed84cf26392d5264c784e9a7f8592b98d0bcba66adc78c0e2d51afa9d7a1"},{"ts":"2026-07-17T02:41:06.553Z","model":"owner","action":"voxel_divide","prompt":"","input":"pt-141-gut","response":"19 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"ddfeed84cf26392d5264c784e9a7f8592b98d0bcba66adc78c0e2d51afa9d7a1","hash":"713515c37a40d09f0fea1d8fa537a2e2f15a9fe87937c10f4a870184d376d75d"}],"energy":{"passes":2,"tokens_in":14847,"tokens_out":2764,"tokens_total":17611,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"713515c37a40d09f0fea1d8fa537a2e2f15a9fe87937c10f4a870184d376d75d"},"posted_at":"2026-06-29T21:32:53.299Z","created_at":"2026-06-29T21:32:53.299Z","updated_at":"2026-07-17T02:41:06.553Z","machine":{"shape":"article.machine/v1","slug":"pt-141-gut","kind":"article","read":{"human":"https://miscsubjects.com/a/pt-141-gut","json":"https://miscsubjects.com/api/articles/pt-141-gut","bundle":"https://miscsubjects.com/api/articles/pt-141-gut/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":3,"sources":4,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/pt-141-gut/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=pt-141-gut","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"pt-141-gut\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"pt-141-gut\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/pt-141-gut/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"pt-141-gut\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/pt-141-gut | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/pt-141-gut","json":"/api/articles/pt-141-gut","markdown":"/api/articles/pt-141-gut/bundle?format=markdown","skill":"/api/articles/pt-141-gut/skill","topology":"/api/articles/pt-141-gut/topology","versions":"/api/articles/pt-141-gut/revisions","invocations":"/api/articles/pt-141-gut/invocations"},"editorial_review":null,"editorial_audit":{"slug":"pt-141-gut","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"6e5f2b4e764a1f2a42d03d71f0a26b0d625429bb655f117329d1ea602bf730be","object":{"object_type":"article-object","identity":{"id":"article:pt-141-gut","slug":"pt-141-gut","title":"PT-141 for Gut: Evidence Review"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/pt-141-gut","role":"explain","audience":"human"},"skill":{"route":"/api/articles/pt-141-gut/skill","role":"direct behavior","audience":"model","content":"---\nname: pt-141-gut\ndescription: Apply the PT-141 for Gut: Evidence Review article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# PT-141 for Gut: Evidence Review\n\nThis Skill is the behavioral expression of [the canonical article](/a/pt-141-gut). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/pt-141-gut.\n- Read claims and relationships at /api/articles/pt-141-gut/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nWhat's breaking down Gut issues often involve layers of degeneration where repair pathways lag behind ongoing stress or inflammation. The melanocortin system, which PT-141 targets in the central nervous system, has some presence in broader \n\n## Representations\n\n- Human: /a/pt-141-gut\n- JSON: /api/articles/pt-141-gut\n- Relationships: /api/articles/pt-141-gut/topology\n- History: /api/articles/pt-141-gut/revisions\n"},"json":{"route":"/api/articles/pt-141-gut","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/pt-141-gut/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["peptide","matrix","pt","141","gut"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/pt-141-gut/invocations?status=success","failure_events":"/api/articles/pt-141-gut/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"pt-141-gut","title":"PT-141 for Gut: Evidence Review","body":"## What's breaking down\n\nGut issues often involve layers of degeneration where repair pathways lag behind ongoing stress or inflammation. The melanocortin system, which PT-141 targets in the central nervous system, has some presence in broader physiology, but direct links to intestinal tissue repair remain unexplored in available data. If your gut symptoms tie into central arousal or motivation pathways, or if side effects like nausea appear, that context matters. PT-141 is not positioned as a gut-specific compound.\n\n## Why PT-141 might help you\n\n1. **Therefore for you:** If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\n\nPT-141 acts centrally on melanocortin receptors, primarily MC4R in the hypothalamus. This pathway influences arousal and motivation. For someone whose gut complaints overlap with disrupted CNS signaling (such as stress-related motility changes), the discussion centers on whether central activation could indirectly support gut-brain communication. No direct tissue repair data exists for intestinal lining or microbiome balance. If your gut problem stems from mechanical or inflammatory breakdown rather than CNS arousal, this mechanism does not address those layers. Side effect reports note slowed gastric emptying and nausea, which could add mechanical load or discomfort rather than relieve it.\n\n## How these fit together\n\nSingle-compound focus. PT-141 maps to the sexual / CNS arousal layer. If your condition profile includes a multi-peptide stack, siblings would target other layers listed in the condition profile. Here the focus stays on one compound and one primary layer.\n\n## What the evidence actually shows\n\nHuman trials of bremelanotide focus on hypoactive sexual desire disorder. Two phase 3 studies measured desire scores and distress but did not assess gastrointestinal endpoints beyond recording adverse events. Nausea occurred in roughly 40 percent of participants at the approved dose, with some reports of stomach pain and slowed gastric emptying. These effects led to cautions for people with existing bowel motility problems. Preclinical work includes one rabbit ileum study where alpha-MSH (related but not identical) produced relaxation; bremelanotide itself showed no comparable effect at the tested concentration. No rodent or human studies demonstrate PT-141 repairing gut mucosa, reducing inflammation markers, or improving motility in disease models. Anecdotal reports on forums mention nausea or stomach upset after use, with no consistent claims of gut improvement.\n\n## What scientists say\n\nPublished reviews describe bremelanotide as a melanocortin agonist acting in the medial preoptic area to increase dopamine release linked to sexual motivation. Gastrointestinal effects appear only in safety sections as dose-dependent adverse events. Researchers note the drug's metabolism involves peptide hydrolysis, with no identified gut-protective pathway. Functional MRI studies in women with HSDD show changes in sexual brain processing but do not extend to gut regions or autonomic control of digestion.\n\n## What people say on Reddit\n\nUsers in threads about PT-141 experiences frequently list nausea, stomach discomfort, or vomiting as first-dose effects that may lessen with repeated lower dosing or antihistamine pretreatment. Some report taking the compound on an empty stomach to reduce queasiness. No posts describe resolution of IBS, ulcer healing, or improved digestion; discussions stay centered on sexual response and side-effect management. Several users note the peptide is destroyed if taken orally due to digestion.\n\n## What people say on X\n\nPosts referencing PT-141 rarely mention gut outcomes. Occasional comments link the compound to broader peptide stacks or note transient nausea. One post in a Huberman Lab discussion thread lists PT-141 alongside other peptides without gut-specific claims. Sentiment remains focused on libido effects rather than digestive repair.\n\n## What we do not know\n\nNo controlled human data exist on PT-141 for any primary gut condition. Long-term effects on gastric emptying or microbiome composition are unstudied. Whether central melanocortin activation could produce secondary benefits in stress-sensitive gut disorders remains speculative. Animal models of intestinal disease have not tested this compound.\n\n## Safety and limits\n\nCommon side effects include nausea, flushing, and headache. The drug carries a caution for use in people with slow gastric emptying because it may worsen the condition and alter absorption of oral medications. It is administered by subcutaneous injection. Evidence grade for any gut benefit is absent; available information addresses sexual function and lists gastrointestinal adverse events. Readers should consult primary sources and qualified professionals for personal decisions.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/pt-141-gut/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"Bremelanotide is approved for HSDD and commonly causes nausea in ~40% of users in phase 3 trials.","section":"What the evidence actually shows","tier":"human","source_ids":["s0","s4"],"source_status":"sourced","why_material":"Establishes the main documented human effect relevant to gut symptoms.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:16:04.509Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"No published human or animal studies show PT-141 repairing intestinal tissue or improving gut motility disorders.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s22"],"source_status":"sourced","why_material":"Clarifies absence of positive gut data.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:16:04.509Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Reddit users report nausea or stomach upset as the dominant gut-related experience with PT-141.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s15"],"source_status":"sourced","why_material":"Documents real-world reports separate from trials.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:16:04.509Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s0","type":"medical","url":"https://www.mayoclinic.org/drugs-supplements/bremelanotide-subcutaneous-route/description/drg-20466805","title":"Bremelanotide (subcutaneous route) - Side effects & dosage","quote":"Stomach or bowel problem (eg, slow gastric emptying)—Use with caution. May make this condition worse and decrease the absorption of oral medicines.","summary":"Mayo Clinic entry lists GI cautions and common side effects including nausea and stomach pain.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:16:04.133Z","link_status":"http_403","quote_status":"unverified","prev":"genesis","hash":"5249c405c2cd8485aef049d45066aaeff0a97fc5b0562c41e01079695ec4390d"},{"id":"s4","type":"other","url":"https://mensreproductivehealth.com/pt-141-for-men-a-new-drug-to-treat-erectile-dysfunction-and-low-libido/","title":"PT-141 FOR MEN","quote":"about 40% of people (based on female trials) experienced nausea after a 1.75 mg dose","summary":"Summarizes trial nausea rates and gastric emptying effects.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:16:04.133Z","link_status":"ok","quote_status":"verified","prev":"5249c405c2cd8485aef049d45066aaeff0a97fc5b0562c41e01079695ec4390d","hash":"46616f84ff4bf6fbb652e40836c0def4ab8458e19e25026fef9b5b79855af28c"},{"id":"s22","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/18587425/","title":"Pharmacological profiling of neuropeptides on rabbit ileum","quote":"The melanocortin agonist alpha-melanocortin-stimulating hormone (1 microM), but not bremelanotide (1 microM), also relaxed both preparations.","summary":"Only related compound showed effect; bremelanotide did not.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:16:04.133Z","link_status":"ok","quote_status":"verified","prev":"46616f84ff4bf6fbb652e40836c0def4ab8458e19e25026fef9b5b79855af28c","hash":"8e998c5e33732bb8c8cafa52a470a68e674cb0bce776a2678accdc9bd0b0bb09"},{"id":"s15","type":"reddit","url":"https://www.reddit.com/r/erectiledysfunction/comments/1qik4vm/pt141_experience_it_absolutely_works/","title":"PT-141 Experience","quote":"No pill form as it is a peptide it would be digested in the stomach.","summary":"User discussion of administration and side effects.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:16:04.133Z","link_status":"ok","quote_status":"unverified","prev":"8e998c5e33732bb8c8cafa52a470a68e674cb0bce776a2678accdc9bd0b0bb09","hash":"0bc46685450ce81ea92026cc60141ec391df3757b8f815c3524e1755dbe6ed9e"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-30T01:16:04.899Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"PT-141 for Gut: Evidence Review","register":"source_ledger","body":"## What's breaking down\n\nGut issues often involve layers of degeneration where repair pathways lag behind ongoing stress or inflammation. The melanocortin system, which PT-141 targets in the central nervous system, has some presence in broader physiology, but direct links to intestinal tissue repair remain unexplored in available data. If your gut symptoms tie into central arousal or motivation pathways, or if side effects like nausea appear, that context matters. PT-141 is not positioned as a gut-specific compound.\n\n## Why PT-141 might help you\n\n1. **Therefore for you:** If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\n\nPT-141 acts centrally on melanocortin receptors, primarily MC4R in the hypothalamus. This pathway influences arousal and motivation. For someone whose gut complaints overlap with disrupted CNS signaling (such as stress-related motility changes), the discussion centers on whether central activation could indirectly support gut-brain communication. No direct tissue repair data exists for intestinal lining or microbiome balance. If your gut problem stems from mechanical or inflammatory breakdown rather than CNS arousal, this mechanism does not address those layers. Side effect reports note slowed gastric emptying and nausea, which could add mechanical load or discomfort rather than relieve it.\n\n## How these fit together\n\nSingle-compound focus. PT-141 maps to the sexual / CNS arousal layer. If your condition profile includes a multi-peptide stack, siblings would target other layers listed in the condition profile. Here the focus stays on one compound and one primary layer.\n\n## What the evidence actually shows\n\nHuman trials of bremelanotide focus on hypoactive sexual desire disorder. Two phase 3 studies measured desire scores and distress but did not assess gastrointestinal endpoints beyond recording adverse events. Nausea occurred in roughly 40 percent of participants at the approved dose, with some reports of stomach pain and slowed gastric emptying. These effects led to cautions for people with existing bowel motility problems. Preclinical work includes one rabbit ileum study where alpha-MSH (related but not identical) produced relaxation; bremelanotide itself showed no comparable effect at the tested concentration. No rodent or human studies demonstrate PT-141 repairing gut mucosa, reducing inflammation markers, or improving motility in disease models. Anecdotal reports on forums mention nausea or stomach upset after use, with no consistent claims of gut improvement.\n\n## What scientists say\n\nPublished reviews describe bremelanotide as a melanocortin agonist acting in the medial preoptic area to increase dopamine release linked to sexual motivation. Gastrointestinal effects appear only in safety sections as dose-dependent adverse events. Researchers note the drug's metabolism involves peptide hydrolysis, with no identified gut-protective pathway. Functional MRI studies in women with HSDD show changes in sexual brain processing but do not extend to gut regions or autonomic control of digestion.\n\n## What people say on Reddit\n\nUsers in threads about PT-141 experiences frequently list nausea, stomach discomfort, or vomiting as first-dose effects that may lessen with repeated lower dosing or antihistamine pretreatment. Some report taking the compound on an empty stomach to reduce queasiness. No posts describe resolution of IBS, ulcer healing, or improved digestion; discussions stay centered on sexual response and side-effect management. Several users note the peptide is destroyed if taken orally due to digestion.\n\n## What people say on X\n\nPosts referencing PT-141 rarely mention gut outcomes. Occasional comments link the compound to broader peptide stacks or note transient nausea. One post in a Huberman Lab discussion thread lists PT-141 alongside other peptides without gut-specific claims. Sentiment remains focused on libido effects rather than digestive repair.\n\n## What we do not know\n\nNo controlled human data exist on PT-141 for any primary gut condition. Long-term effects on gastric emptying or microbiome composition are unstudied. Whether central melanocortin activation could produce secondary benefits in stress-sensitive gut disorders remains speculative. Animal models of intestinal disease have not tested this compound.\n\n## Safety and limits\n\nCommon side effects include nausea, flushing, and headache. The drug carries a caution for use in people with slow gastric emptying because it may worsen the condition and alter absorption of oral medications. It is administered by subcutaneous injection. Evidence grade for any gut benefit is absent; available information addresses sexual function and lists gastrointestinal adverse events. Readers should consult primary sources and qualified professionals for personal decisions.","claims":[{"id":"c1","text":"Bremelanotide is approved for HSDD and commonly causes nausea in ~40% of users in phase 3 trials.","section":"What the evidence actually shows","tier":"human","source_ids":["s0","s4"],"source_status":"sourced","why_material":"Establishes the main documented human effect relevant to gut symptoms.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:16:04.509Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"No published human or animal studies show PT-141 repairing intestinal tissue or improving gut motility disorders.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s22"],"source_status":"sourced","why_material":"Clarifies absence of positive gut data.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:16:04.509Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Reddit users report nausea or stomach upset as the dominant gut-related experience with PT-141.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s15"],"source_status":"sourced","why_material":"Documents real-world reports separate from trials.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:16:04.509Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s0","type":"medical","url":"https://www.mayoclinic.org/drugs-supplements/bremelanotide-subcutaneous-route/description/drg-20466805","title":"Bremelanotide (subcutaneous route) - Side effects & dosage","quote":"Stomach or bowel problem (eg, slow gastric emptying)—Use with caution. May make this condition worse and decrease the absorption of oral medicines.","link_status":"http_403","quote_status":"unverified"},{"id":"s4","type":"other","url":"https://mensreproductivehealth.com/pt-141-for-men-a-new-drug-to-treat-erectile-dysfunction-and-low-libido/","title":"PT-141 FOR MEN","quote":"about 40% of people (based on female trials) experienced nausea after a 1.75 mg dose","link_status":"ok","quote_status":"verified"},{"id":"s22","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/18587425/","title":"Pharmacological profiling of neuropeptides on rabbit ileum","quote":"The melanocortin agonist alpha-melanocortin-stimulating hormone (1 microM), but not bremelanotide (1 microM), also relaxed both preparations.","link_status":"ok","quote_status":"verified"},{"id":"s15","type":"reddit","url":"https://www.reddit.com/r/erectiledysfunction/comments/1qik4vm/pt141_experience_it_absolutely_works/","title":"PT-141 Experience","quote":"No pill form as it is a peptide it would be digested in the stomach.","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":14847,"tokens_out":2764,"cost":0.02546875,"prev_hash":"genesis","hash":"05815fb669fb21707ab4f425b35bed80adcb8b7225f66cc560242f14a9601307"}],"provenance":[{"ts":"2026-06-30T01:16:04.899Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: PT 141 for Gut\nSlug: pt-141-gut\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"pt-141\",\"name\":\"PT-141\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"pt-141\",\"name\":\"PT-141\",\"section_title\":\"Why PT-141 might help you\",\"layer\":\"sexual / CNS arousal\",\"steps\":[\"**Therefore for you:** If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. **Therefore for you:** If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **PT-141** → sexual / CNS arousal\",\"section_headings\":[\"What's breaking down\",\"Why PT-141 might help you\",\"How these fit together\",\"What the evidence actually shows\",\"What scientists say\",\"What people say on Reddit\",\"What people say on X\",\"What we do not know\",\"Safety and limits\"],\"writer_rules\":[\"One ## section per compound in peptide_chains — do not merge into one peptide essay.\",\"Each Why section must use if-then steps from peptide_chains / ","response":"{\n  \"slug\": \"pt-141-gut\",\n  \"title\": \"PT-141 for Gut: Evidence Review\",\n  \"body\": \"## What's breaking down\\n\\nGut issues often involve layers of degeneration where repair pathways lag behind ongoing stress or inflammation. The melanocortin system, which PT-141 targets in the central nervous system, has some presence in broader physiology, but direct links to intestinal tissue repair remain unexplored in available data. If your gut symptoms tie into central arousal or motivation pathways, or if side effects like nausea appear, that context matters. PT-141 is not positioned as a gut-specific compound.\\n\\n## Why PT-141 might help you\\n\\n1. **Therefore for you:** If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\\n\\nPT-141 acts centrally on melanocortin receptors, primarily MC4R in the hypothalamus. This pathway influences arousal and motivation. For someone whose gut complaints overlap with disrupted CNS signaling (such as stress-related motility changes), the discussion centers on whether central activation could indirectly support gut-brain communication. No direct tissue repair data exists for intestinal lining or microbiome balance. If your gut problem stems from mechanical or inflammatory breakdown rather than CNS arousal, this mechanism does not address those layers. Side effect reports note slowed gastric emptying and nausea, which could add mechanical load or discomfort rather than relieve it.\\n\\n## How these fit together\\n\\nSingle-compound focus. PT-141 maps to the sexual / CNS arousal layer. If your condition profile includes a multi-peptide stack, siblings would target other layers listed in the condition profile. Here the focus stays on one compound and one primary layer.\\n\\n## What the evidence actually shows\\n\\nHuman trials of bremelanotide focus on hypoactive sexual desire disorder. Two phase 3 studies measured desire scores and distress but did not assess gastrointestinal endpoints ","tokens_in":14847,"tokens_out":2764,"cost":0,"prev":"genesis","hash":"ddfeed84cf26392d5264c784e9a7f8592b98d0bcba66adc78c0e2d51afa9d7a1"},{"ts":"2026-07-17T02:41:06.553Z","model":"owner","action":"voxel_divide","prompt":"","input":"pt-141-gut","response":"19 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"ddfeed84cf26392d5264c784e9a7f8592b98d0bcba66adc78c0e2d51afa9d7a1","hash":"713515c37a40d09f0fea1d8fa537a2e2f15a9fe87937c10f4a870184d376d75d"}],"energy":{"passes":2,"tokens_in":14847,"tokens_out":2764,"tokens_total":17611,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"713515c37a40d09f0fea1d8fa537a2e2f15a9fe87937c10f4a870184d376d75d"},"posted_at":"2026-06-29T21:32:53.299Z","created_at":"2026-06-29T21:32:53.299Z","updated_at":"2026-07-17T02:41:06.553Z","machine":{"shape":"article.machine/v1","slug":"pt-141-gut","kind":"article","read":{"human":"https://miscsubjects.com/a/pt-141-gut","json":"https://miscsubjects.com/api/articles/pt-141-gut","bundle":"https://miscsubjects.com/api/articles/pt-141-gut/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":3,"sources":4,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/pt-141-gut/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=pt-141-gut","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"pt-141-gut\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"pt-141-gut\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/pt-141-gut/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"pt-141-gut\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/pt-141-gut | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/pt-141-gut","json":"/api/articles/pt-141-gut","markdown":"/api/articles/pt-141-gut/bundle?format=markdown","skill":"/api/articles/pt-141-gut/skill","topology":"/api/articles/pt-141-gut/topology","versions":"/api/articles/pt-141-gut/revisions","invocations":"/api/articles/pt-141-gut/invocations"},"editorial_review":null,"editorial_audit":{"slug":"pt-141-gut","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"6e5f2b4e764a1f2a42d03d71f0a26b0d625429bb655f117329d1ea602bf730be"}}}